Without a right to say no, people cannot refuse the uses their genome is put to

The argument

A second argument for ownership is practical rather than conceptual: it concerns who decides what happens to a sample after it is given. Genetic material is now collected in many settings, from clinical care to ancestry services to criminal investigation, and proponents argue that in most of them the person giving the sample agrees to a broad purpose once and then has no further say. The sample may be stored indefinitely, re-analysed as techniques improve, shared with partner organisations, transferred when a company is sold, or used for research the donor never contemplated, and the consent that covers all of this was obtained before any of it was specified. Proponents argue that consent of that kind is not meaningful because it cannot be exercised. A person who later objects to a use has no mechanism to compel deletion, no claim on the value created, and often no way to find out what was done. An ownership right changes this by giving the individual continuing standing: a basis to require that a sample be destroyed, to restrict transfer to third parties, to withhold permission for a new category of analysis, and to be asked again when the purpose changes materially. The point is not primarily to let people charge for access but to give them a position from which refusal is possible. The commercial dimension strengthens the claim rather than driving it. Genetic data is valuable, and that value is realised by organisations holding large collections of it. Proponents argue that an arrangement in which the material is supplied by individuals and the proceeds accrue entirely to collectors is hard to defend on any account of fairness, and that recognising the individual as the owner at least makes the terms of exchange explicit and negotiable rather than assumed.

Premises

Counter-arguments

Critics argue the problem is real but the remedy misdescribed. Everything proponents want, from deletion on request to limits on transfer and fresh consent for new purposes, is a matter of regulating how holders behave, and several data protection regimes already grant exactly these rights without treating genomes as property. Making DNA ownable, they warn, converts a protection into an asset: once it can be owned it can be sold, pledged or inherited, and employers, insurers and platforms will find ways to make parting with it a condition of something people need. Critics add that the fairness point about commercial value cuts the other way, since most of the value comes from aggregating many genomes and from the analysis applied to them rather than from any one sample.

Rejecting the premises

[Rejecting P1] Broad consent is a defect in consent practice that can be fixed by requiring specific, renewable permissions, which does not require an ownership right. [Rejecting P2] Deletion, restriction of transfer and renewed consent are already granted as data protection rights in several jurisdictions, so the gap is enforcement rather than ownership. [Rejecting P3] A right that can be owned can be sold or made a condition of employment, insurance or service, which would weaken the very refusal it was meant to secure. [Rejecting C] If the aim is to make refusal possible, duties on holders achieve it more directly than a transferable property right in one's genome.